CoChat

Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?

Open access
DePaoli, Alex M., Higgins, Linda S., Henry, Robert R., Mantzoros, Christos, Dunn, Fredrick L. · 2014 · Diabetes Care
Cited by 79

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: INT131 besylate is a potent, nonthiazolidinedione, selective peroxisome proliferator–activated receptor γ (PPARγ) modulator (SPPARM) designed to improve glucose metabolism while minimizing the side effects of full PPARγ agonists. This placebo-controlled study compared the efficacy and side effects of INT131 besylate versus 45 mg pioglitazone HCl in subjects with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This was a 24-week randomized, double-blind, placebo- and active-controlled study of 0.5–3.0 mg INT131 versus 45 mg pioglitazone or placebo daily in 367 subjects with T2D on sulfonylurea or sulfonylurea plus metformin. The primary efficacy analysis was the comparison of change from baseline to week 24 in hemoglobin A1c (HbA1c) across treatment groups. Fluid status was assessed with a prospective scoring system for lower-extremity pitting edema. RESULTS: INT131 had a steep dose response for efficacy as measured by changes in HbA1c. After 24 weeks’ treatment, the 0.5-mg dose demonstrated minimal efficacy (HbA1c −0.3 ± 0.12%) and the 2-mg dose demonstrated near-maximal efficacy (HbA1c −1.1 ± 0.12%), which was not statistically different from the efficacy of 45 mg pioglitazone (HbA1c −0.9 ± 0.12%; P < 0.01 for noninferiority). With the 1-mg dose, INT131 provided significant improvements in glycemic control (HbA1c 0.8 ± 0.12; P < 0.001 vs. placebo) but with less edema, weight gain, and hemodilution than observed with 45 mg pioglitazone. CONCLUSIONS: INT131 demonstrated dose-dependent reductions in HbA1c, equivalent to 45 mg pioglitazone, but with less fluid accumulation and weight gain, consistent with its SPPARM design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-2480

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 20

  1. Olefsky, 2000, Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists, J Clin Invest, 106, 467, 10.1172/JCI10843 · DOI · Paper page
  2. Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
  3. Graham, 2010, Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone, JAMA, 304, 411, 10.1001/jama.2010.920 · DOI · Paper page
  4. Murphy, 2007, Effects of thiazolidinediones on bone loss and fracture, Ann Pharmacother, 41, 2014, 10.1345/aph.1K286 · DOI · Paper page
  5. Mudaliar, 2003, Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications, Endocr Pract, 9, 406, 10.4158/EP.9.5.406 · DOI · Paper page
  6. Nesto, 2004, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Diabetes Care, 27, 256, 10.2337/diacare.27.1.256 · DOI · Paper page
  7. Lago, 2007, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet, 370, 1129, 10.1016/S0140-6736(07)61514-1 · DOI · Paper page
  8. Higgins, 2008, The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer, PPAR Res, 2008, 936906, 10.1155/2008/936906 · DOI
  9. Higgins, 2010, Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation, Am J Clin Nutr, 91, 267S, 10.3945/ajcn.2009.28449E · DOI · Paper page
  10. Motani, 2009, INT131: a selective modulator of PPAR γ, J Mol Biol, 386, 1301, 10.1016/j.jmb.2009.01.025 · DOI
  11. Lee, 2012, Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice, Am J Physiol Endocrinol Metab, 302, E552, 10.1152/ajpendo.00569.2011 · DOI
  12. Waites, 2007, Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/γ agonist, Toxicol Sci, 100, 248, 10.1093/toxsci/kfm193 · DOI
  13. DePaoli, 2008, INT131, a non-TZD selective PPARγ modulator (SPPARM), does not cause toxicities typical of TZD full PPARγ agonists following 6-month high dose treatment of rats or monkeys, Diabetologia, 51, S369
  14. Dunn, 2011, Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes, J Diabetes Complications, 10.1016/j.jdiacomp.2010.06.006 · DOI
  15. Lebovitz, 2001, Rosiglitazone monotherapy is effective in patients with type 2 diabetes, J Clin Endocrinol Metab, 86, 280, 10.1210/jcem.86.1.7157 · doi:10.1210/jcem.86.1.7157 · Paper page
  16. Pavo, 2003, Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes, J Clin Endocrinol Metab, 88, 1637, 10.1210/jc.2002-021786 · DOI · Paper page
  17. Raskin, 2000, Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes, Diabetologia, 43, 278, 10.1007/s001250050045 · DOI · Paper page
  18. Berger, 2003, Distinct properties and advantages of a novel peroxisome proliferator-activated protein [γ] selective modulator, Mol Endocrinol, 17, 662, 10.1210/me.2002-0217 · DOI · Paper page
  19. Zhang, 2007, Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects, PPAR Res, 2007, 32696, 10.1155/2007/32696 · DOI
  20. Kersey, 2004, T0903131, a selective modulator of PPAR–gamma activity, increases adiponectin levels in healthy subjects (Abstract), Diabetes, 53, A156

Cited by

See all 79

Metadata

Authors
DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., & Dunn, F. L.
Venue
Diabetes Care
Published
2014-06-12
Volume
37
Issue
7
Pages
1918-1923
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1977484873
Cited by
79
References
3
FWCI
3.41
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? https://app.cochat.ai/papers/10.2337/dc13-2480
The paper
DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., & Dunn, F. L. (2014). Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? Diabetes Care. https://doi.org/10.2337/dc13-2480

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.